Spyre Therapeutics director sells 20,000 SYRE shares

Spyre Therapeutics director Michael Thomas Henderson reported an open-market sale of Common Stock.

Rhea-AI Filing Summary

Spyre Therapeutics director Michael Thomas Henderson reported an open-market sale of Common Stock. He sold 20,000 shares on June 22, 2026 at a price of $100.00 per share. After this transaction, he directly holds 68,606 shares of Spyre Therapeutics common stock.

According to a footnote, this sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating the trades were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 20,000 shares

Net Sell 1 txn

Insider HENDERSON MICHAEL THOMAS

Role Director

Sold 20,000 shs ($2.00M)

Type	Security	Shares	Price	Value
Sale	Common Stock	20,000	$100.00	$2.00M

Holdings After Transaction: Common Stock — 68,606 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.

Key Figures

Shares sold: 20,000 shares Sale price per share: $100.00 per share Shares held after transaction: 68,606 shares +2 more

5 metrics

Shares sold 20,000 shares Open-market sale of Common Stock on June 22, 2026

Sale price per share $100.00 per share Transaction price for Common Stock sale

Shares held after transaction 68,606 shares Direct ownership after June 22, 2026 sale

Transaction code S Sale in open market or private transaction

Trading plan adoption date February 6, 2026 Rule 10b5-1 trading plan used for this sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Spyre Therapeutics (SYRE) director Michael Thomas Henderson report in this Form 4?

He reported an open-market sale of 20,000 shares of Spyre Therapeutics Common Stock at $100.00 per share on June 22, 2026. Following the sale, his direct holdings total 68,606 shares of the company’s common stock.

How many Spyre Therapeutics (SYRE) shares does Michael Thomas Henderson hold after the sale?

After the reported transaction, Michael Thomas Henderson directly holds 68,606 shares of Spyre Therapeutics Common Stock. This figure reflects his position after selling 20,000 shares in the open market at $100.00 per share on June 22, 2026.

Was the Spyre Therapeutics (SYRE) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026. Such plans pre-schedule trades, indicating the timing of this 20,000-share sale was determined in advance rather than decided opportunistically.

What type of transaction did Spyre Therapeutics (SYRE) report for director Michael Thomas Henderson?

The filing reports a non-derivative open-market sale of Common Stock, coded “S” for sale. He sold 20,000 shares at $100.00 each, reducing his direct holdings to 68,606 shares after the transaction on June 22, 2026.

Does the Spyre Therapeutics (SYRE) Form 4 show any option exercises or derivative transactions?

No derivative transactions are listed in the provided data. The filing shows only a non-derivative open-market sale of 20,000 Common Stock shares and indicates no remaining derivative positions in the derivative summary section for this reporting event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 09:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENDERSON MICHAEL THOMAS

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		S(1)		20,000	D	$100	68,606	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)